Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 136

1.

Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models.

Corrales-Medina FF, Manton CA, Orlowski RZ, Chandra J.

Leuk Res. 2015 Jan 3. pii: S0145-2126(14)00409-3. doi: 10.1016/j.leukres.2014.12.014. [Epub ahead of print]

PMID:
25612941
[PubMed - as supplied by publisher]
2.

Bayesian joint selection of genes and pathways: applications in multiple myeloma genomics.

Zhang L, Morris JS, Zhang J, Orlowski RZ, Baladandayuthapani V.

Cancer Inform. 2014 Dec 7;13(Suppl 2):113-23. doi: 10.4137/CIN.S13787. eCollection 2014.

PMID:
25520554
[PubMed]
Free PMC Article
3.

Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis.

Shi Q, Wang XS, Li G, Shah ND, Orlowski RZ, Williams LA, Mendoza TR, Cleeland CS.

Cancer. 2014 Dec 2. doi: 10.1002/cncr.29154. [Epub ahead of print]

PMID:
25469832
[PubMed - as supplied by publisher]
4.

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS.

Lancet Oncol. 2014 Nov;15(12):1311-8. doi: 10.1016/S1470-2045(14)70455-3. Epub 2014 Oct 15.

PMID:
25439689
[PubMed - in process]
5.

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma.

Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos MA, Cavenagh JD, Špička I, Maiolino A, Suvorov A, Bladé J, Samoylova O, Puchalski TA, Reddy M, Bandekar R, van de Velde H, Xie H, Rossi JF.

Am J Hematol. 2015 Jan;90(1):42-9. doi: 10.1002/ajh.23868.

PMID:
25294016
[PubMed - in process]
6.

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.

Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, Benboubker L, Roddie H, Potamianou A, Couturier C, Feng H, Ataman O, van de Velde H, Richardson PG.

Haematologica. 2015 Jan;100(1):100-6. doi: 10.3324/haematol.2014.112037. Epub 2014 Sep 26.

PMID:
25261096
[PubMed - in process]
Free PMC Article
7.

Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma.

Wang XS, Shi Q, Williams LA, Shah ND, Mendoza TR, Cohen EN, Reuben JM, Cleeland CS, Orlowski RZ.

Leuk Lymphoma. 2014 Nov 20:1-7. [Epub ahead of print]

PMID:
25248883
[PubMed - as supplied by publisher]
8.

A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis.

Chen S, Zhang Y, Zhou L, Leng Y, Lin H, Kmieciak M, Pei XY, Jones R, Orlowski RZ, Dai Y, Grant S.

Blood. 2014 Oct 23;124(17):2687-97. doi: 10.1182/blood-2014-03-564534. Epub 2014 Sep 10.

PMID:
25208888
[PubMed - in process]
9.

Inhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737.

Gu D, Wang S, Kuiatse I, Wang H, He J, Dai Y, Jones RJ, Bjorklund CC, Yang J, Grant S, Orlowski RZ.

PLoS One. 2014 Sep 2;9(9):e103015. doi: 10.1371/journal.pone.0103015. eCollection 2014.

PMID:
25181509
[PubMed - in process]
Free PMC Article
10.

Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia.

Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH.

Clin Lymphoma Myeloma Leuk. 2014 Jul 15. pii: S2152-2650(14)00261-4. doi: 10.1016/j.clml.2014.07.001. [Epub ahead of print]

PMID:
25107338
[PubMed - as supplied by publisher]
11.

Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.

Wen J, Tao W, Kuiatse I, Lin P, Feng Y, Jones RJ, Orlowski RZ, Zu Y.

Int J Cancer. 2015 Mar 1;136(5):991-1002. doi: 10.1002/ijc.29078. Epub 2014 Jul 23.

PMID:
25042852
[PubMed - in process]
12.

Targeting SQSTM1/p62 induces cargo loading failure and converts autophagy to apoptosis via NBK/Bik.

Chen S, Zhou L, Zhang Y, Leng Y, Pei XY, Lin H, Jones R, Orlowski RZ, Dai Y, Grant S.

Mol Cell Biol. 2014 Sep 15;34(18):3435-49. doi: 10.1128/MCB.01383-13. Epub 2014 Jul 7.

PMID:
25002530
[PubMed - indexed for MEDLINE]
13.

The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma.

Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, Wang M, Qazilbash MH, Baladandayuthapani V, Berry D, Orlowski RZ, Lee MH, Yeung SC.

Br J Cancer. 2014 Jul 29;111(3):628-36. doi: 10.1038/bjc.2014.307. Epub 2014 Jun 12.

PMID:
24921909
[PubMed - indexed for MEDLINE]
14.

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.

Srkalovic G, Hussein MA, Hoering A, Zonder JA, Popplewell LL, Trivedi H, Mazzoni S, Sexton R, Orlowski RZ, Barlogie B.

Cancer Med. 2014 Oct;3(5):1275-83. doi: 10.1002/cam4.276. Epub 2014 Jun 10.

PMID:
24913924
[PubMed - in process]
Free PMC Article
15.

Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.

Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, Shah N, Popat U, Giralt SA, Orlowski RZ, Qazilbash MH.

Bone Marrow Transplant. 2014 Aug;49(8):1036-41. doi: 10.1038/bmt.2014.115. Epub 2014 Jun 2.

PMID:
24887378
[PubMed - in process]
16.

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.

Garcia MK, Cohen L, Guo Y, Zhou Y, You B, Chiang J, Orlowski RZ, Weber D, Shah J, Alexanian R, Thomas S, Romaguera J, Zhang L, Badillo M, Chen Y, Wei Q, Lee R, Delasalle K, Green V, Wang M.

J Hematol Oncol. 2014 May 9;7(1):41. doi: 10.1186/1756-8722-7-41.

PMID:
24886772
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.

Glitza IC, Lu G, Shah R, Bashir Q, Shah N, Champlin RE, Shah J, Orlowski RZ, Qazilbash MH.

Leuk Lymphoma. 2014 Aug 18:1-6. [Epub ahead of print]

PMID:
24844357
[PubMed - as supplied by publisher]
18.

Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.

San-Miguel J, Bladé J, Shpilberg O, Grosicki S, Maloisel F, Min CK, Polo Zarzuela M, Robak T, Prasad SV, Tee Goh Y, Laubach J, Spencer A, Mateos MV, Palumbo A, Puchalski T, Reddy M, Uhlar C, Qin X, van de Velde H, Xie H, Orlowski RZ.

Blood. 2014 Jun 26;123(26):4136-42. doi: 10.1182/blood-2013-12-546374. Epub 2014 May 15.

PMID:
24833354
[PubMed - indexed for MEDLINE]
19.

Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses.

Coughlin K, Anchoori R, Iizuka Y, Meints J, MacNeill L, Vogel RI, Orlowski RZ, Lee MK, Roden RB, Bazzaro M.

Clin Cancer Res. 2014 Jun 15;20(12):3174-86. doi: 10.1158/1078-0432.CCR-13-2658. Epub 2014 Apr 11.

PMID:
24727327
[PubMed - in process]
20.

Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells.

Pei XY, Dai Y, Felthousen J, Chen S, Takabatake Y, Zhou L, Youssefian LE, Sanderson MW, Bodie WW, Kramer LB, Orlowski RZ, Grant S.

PLoS One. 2014 Mar 4;9(3):e89064. doi: 10.1371/journal.pone.0089064. eCollection 2014.

PMID:
24594907
[PubMed - in process]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk